Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I first-in-human trial to evaluate the safety and immunogenicity of the COVID-19 vaccine candidate in healthy human participants

Next Previous
X
Search
Trial Profile

Phase I first-in-human trial to evaluate the safety and immunogenicity of the COVID-19 vaccine candidate in healthy human participants

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 mRNA vaccine PopVax (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 19 Nov 2024 New trial record
    • 13 Nov 2024 According to PopVax media release, the company is pleased to announce that it has been selected for inclusion in the U.S. Governments Project NextGen. As part of this initiative, the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), will conduct and sponsor this trial which is expected to begin in early 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top